Healthcare Industry News: drug-eluting stent
News Release - October 30, 2008
Medtronic to Launch Coronary Stents and Balloon Catheters on Rapid Exchange in United States
Endeavor(R) drug-eluting stent Now Available on Rapid Exchange Delivery SystemMINNEAPOLIS--(HSMN NewsFeed)--Medtronic, Inc. (NYSE: MDT ), announced today that it plans to launch its portfolio of angioplasty products in the United States on the rapid exchange (RX) delivery system, including the Endeavor® drug-eluting stent (DES), the Driver® and MicroDriver® bare-metal stents, and the NC (non-compliant) Sprinter® balloon catheter systems.
Used in angioplasty procedures to treat coronary artery disease, RX is a short-, single-wire delivery system that can be used by one operator. It is the preferred delivery system of approximately three-quarters of U.S. interventional cardiologists. Medtronic anticipates that access to RX will increase usage of its angioplasty products in the United States.
“RX is a prescription for greater success in cardiac catheterization laboratories nationwide going forward,” said Sean Salmon, vice president and general manager of the Coronary and Peripheral Vascular business at Medtronic. “Delivering the Endeavor stent on RX makes our flagship DES even more deliverable. Given the popularity of RX among physicians, patients with coronary artery disease across the country will soon be much more likely to receive the Endeavor stent, which has demonstrated both long-term safety and durable efficacy in extensive clinical research.”
ABOUT MEDTRONIC
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 25, 2008. Actual results may differ materially from anticipated results.
Source: Medtronic
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
Related News Items
Medtronic Advances Abbott CGM Partnership with FDA Submission of Interoperable Insulin PumpMedtronic appoints Thierry Piéton as Chief Financial Officer
Medtronic Achieves CE Mark Approval for BrainSense Adaptive Deep Brain Stimulation and Electrode Identifier, a Groundbreaking Advance In Personalized, Sensing-Enabled Care for People with Parkinson's Through Innovative Brain-Computer Interface Technology
